TCRT · Alaunos Therapeutics, Inc.
$1.84
-0.06 (-3.16%)
At close · Jul 30
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We require substantial additional financial resources to continue as a going concern and advance our Obesity and Metabolic Disorders Program; the failure to obtain it on acceptable terms would materially harm our business.”View the 10-Q filed May 15, 2026
Market Cap
$46.40M
Shares
24.42M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Melinda Lackey | Legal & Administration, Corporate Secretary | $430,370 |
| Kevin Boyle | CEO | $392,500 |
| Dale Curtis Hogue | CEO | $308,344 |
| Ferdinand Groenewald | Vice President, Finance | $162,304 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Melinda Lackey | Legal & Administration, Corporate Secretary | $701,737 |
| Drew Deniger | Vice President of Research and Development | $629,680 |
| Dale Curtis Hogue | CEO | $48,153 |
| Ferdinand Groenewald | Vice President, Finance | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Kevin Boyle | CEO | $1,792,818 |
| Drew Deniger | Vice President of Research and Development | $949,113 |
| Melinda Lackey | Legal & Administration, Corporate Secretary | $764,743 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kevin Boyle | CEO | $4,573,753 |
| Heidi Hagen | CEO | $2,730,871 |
| Eleanor de Groot | Executive Vice President and GM of Cell Therapy | $2,174,017 |
| Jill Buck | Executive Vice President, General Manager, Gene Therapy | $1,873,742 |
| Laurence James Neil Cooper | CEO | $1,531,130 |
| Raffaele Baffa | Chief Medical Officer | $1,034,270 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Laurence James Neil Cooper | CEO | $3,007,922 |
| Raffaele Baffa | Chief Medical Officer | $1,673,584 |
| Satyavrat Shukla | CFO | $1,252,211 |
| Robert Hadfield | Chief Legal Officer and Secretary | $1,006,811 |
| Eleanor de Groot | Executive Vice President and GM of Cell Therapy | $935,112 |
| Heidi Hagen | CEO | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Laurence James Neil Cooper | CEO | $3,317,574 |
| Satyavrat Shukla | CFO | $1,822,218 |
| David Mauney | President | $1,448,931 |
| Robert Hadfield | Chief Legal Officer and Secretary | $1,081,822 |
| Kevin G. Lafond | Chief Accounting Officer | $843,123 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Laurence James Neil Cooper | CEO | $1,589,239 |
| Robert Hadfield | Chief Legal Officer and Secretary | $836,091 |
| David Mauney | President | $608,756 |
| Kevin G. Lafond | Chief Accounting Officer | $398,998 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Laurence James Neil Cooper | CEO | $2,894,244 |
| David Mauney | President | $2,297,974 |
| Kevin G. Lafond | Chief Accounting Officer | $581,224 |